Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int

97
Qué TARV iniciar
Autores: George Rutherford, Alicen Spaulding
Fecha: 8 Oct 2009
Pregunta: ¿Debe utilizarse EFV o NVP en el TARV inicial? (ECAs)
Entornos: Multiples entornos
Bibliografía: 1. Ayala Gaytan JJ, de la Garza ERZ, Garcia MC, Chavez SBV. Nevirapine or efavirenz in combination with two
nucleoside analogues in HIV infected antiretroviral naive patients. Med Intern Mex 2004;20:24. 2. Manosuthi W,
Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Buraptarawong S, Thongyen
S, Likanonsakul S, Thawornwa U, Prommool V, Kuxrungtham K, 2NR Study Team. A randomized trial comparing
plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens
in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 2009;48:1752-9. 3. Núñez M, Soriano V,
Martín-Carbonero L, Barrios A, Barreiro P, Blanco F, García-Benayas T, González-Lahoz J. SENC (Spanish Efavirenz
vs. Nevirapine Comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials
2002;3:186-94. 4. Sow PG, Badiane M, Diallo PD, Lo I, Ndiaye B, Gaye AM. Efficacy and safety of lamivudine +
zidovudine + efavirenz and lamivudine + zidovudine + névirapine in treatment HIV1 infected patients. A rétrospective
cross study analysis [Abstract CDB0584]. XVI International AIDS Conference, Toronto, Canada, 13−18 August 2006. 5.
van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study
Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for
Strategic Initiative in Global HIV Trials (INSIGHT). Virologic, immunologic, clinical, safety, and resistance outcomes
from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in
HIV-1-infected persons. HIV Clin Trials 2008;9:324-36. 6. van Leth F, Kappelhoff BS, Johnson D, Losso MH, Boron-
Kaczmarska A, Saag MS, Hall DB, Leith J, Huitema AD, Wit FW, Beljnen JH, Lange JM; 2NN Study Group.
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses
2006;22:232-39.